AI in Healthcare Statistics 2026

AI is now part of routine medical work for many clinicians, but using an AI tool is not the same as demonstrating that it improves patient care. That distinction is central to understanding the healthcare AI statistics in 2026.

In a survey published in March 2026, the American Medical Association (AMA) found that 81% of responding physicians used AI professionally, more than double the share reported when the AMA first surveyed physicians on the subject in 2023. Doctors reported using AI for tasks ranging from summarizing medical research to preparing documentation and patient instructions.

Healthcare organizations are adopting AI across clinical and administrative workflows, too. A peer-reviewed survey of 43 large U.S. health systems found that 90% had deployed AI for imaging and radiology in at least limited areas, while every responding system had begun developing, piloting or deploying ambient AI documentation. Yet reported success varied substantially by application.

Investment and regulatory activity are also substantial. AI-enabled companies received 54% of U.S. digital health venture funding in 2025, according to Rock Health. Meanwhile, the U.S. Food and Drug Administration (FDA) reported that it had authorized more than 1,600 AI-enabled medical devices for marketing as of September 2026. Neither figure, by itself, establishes how widely those products are used or how well they perform in everyday care.

The most useful way to read the numbers is to separate adoption, deployment, investment, clinical performance and patient outcomes. Each measures a different part of healthcare AI's progress.

Key AI in Healthcare Statistics for 2026

How Many Doctors Are Using AI in 2026?

The AMA's 2026 survey found that 81% of responding physicians used AI in their professional work. The organization reported that this was more than twice the rate observed in its 2023 survey. More than three-quarters of respondents also believed AI improved their ability to care for patients, although that belief is a measure of physician perception rather than a clinical outcome study.

The individual use cases reveal what adoption currently looks like:

The pattern is significant. AI use for information synthesis and documentation is more commonly reported than AI use for assistive diagnosis. The headline adoption figure therefore should not be interpreted to mean that 81% of physicians rely on AI to diagnose patients.

The AMA also found that physicians held mixed feelings about the technology: approximately 40% described themselves as both excited and concerned about AI's role in healthcare. Patient privacy and the integrity of the patient–physician relationship were among their principal concerns.

How Widely Are Hospitals and Health Systems Deploying AI?

Hospital adoption statistics need especially careful interpretation. A health system can be developing a tool, running a pilot, deploying it in a few departments or using it across its entire organization. Those are not equivalent stages.

A study published in the Journal of the American Medical Informatics Association surveyed 43 U.S. nonprofit health systems in fall 2024. The respondents were members of the Scottsdale Institute, and many were large, well-resourced organizations. Its results offer a detailed view of early deployment among those systems, not a representative adoption rate for all U.S. hospitals in 2026.

AI deployment by healthcare use case

The study also found that all 43 responding systems had at least begun developing, piloting or deploying ambient notes. However, only 14% reported full deployment at the time of the survey. The distinction between any activity and full deployment is essential when comparing healthcare AI adoption claims.

Deployment does not guarantee success

The same researchers asked health systems about their perceived success with different categories of AI.

Among organizations pursuing the relevant category, 53% reported a high degree of success with clinical documentation, compared with 38% for clinical risk stratification, 23% for revenue-cycle applications and 19% for clinical diagnosis. These are organizational assessments of success, not measured improvements in diagnostic accuracy, survival or other patient outcomes.

That contrast is one of the most informative findings in the available research: some clinical AI applications are widely deployed without producing equally widespread reports of high success. Healthcare organizations need to evaluate what happens after implementation, not just whether a tool has been installed.

AI in Healthcare Market Size and Growth Forecasts

Market reports consistently forecast growth in healthcare AI, but their dollar estimates depend on the technologies, services, geographies and healthcare activities included.

For example, an April 2025 forecast from Grand View Research projected that the global AI in healthcare market would reach $187.7 billion by 2030, with a stated CAGR of 38.5% over its forecast period. A newer report from the same publisher, released in January 2026, projected $505.59 billion by 2033, with a stated CAGR of 38.9% from 2026 to 2033.

Those figures are publisher forecasts, not observed market revenue. Their different target years and report vintages also mean they should not be treated as one continuous series without checking the underlying definitions and methodology.

A market-size figure is distinct from several other numbers commonly presented alongside it. Venture funding measures capital invested in companies. Hospital spending measures what healthcare organizations purchase. Potential economic value estimates the benefits AI might create. None is interchangeable with revenue earned by companies selling healthcare AI products and services.

For AI Tool Hunt readers comparing market reports, the most useful questions are: What exactly counts as healthcare AI? Does the estimate include software, hardware and services? Does it cover pharmaceutical research and medical devices as well as healthcare delivery? Is the number an observed result or a forecast?

Healthcare AI Investment Statistics

Rock Health reported that U.S. digital health startups raised $14.2 billion across 482 deals in 2025, up 35% from the $10.5 billion raised in 2024. AI-enabled companies accounted for 50% of deals and 54% of total funding in 2025; their funding share was 37% in 2024.

These figures show where venture investors allocated capital within Rock Health's U.S. digital health dataset. They do not mean that 54% of all global healthcare investment went to AI or that AI companies generated 54% of healthcare revenue.

The investment picture is also concentrated. Rock Health reported that large funding rounds had an outsized influence on 2025 totals, with mega-deals accounting for 42% of funding. A rising funding total can therefore coexist with difficult conditions for smaller startups.

AI's appeal to investors is understandable: healthcare has expensive administrative processes, large volumes of clinical data and persistent pressure to improve access and efficiency. But funding is an early signal of commercial expectations, not proof that a product improves care or produces a positive return for its customers.

How Many AI Medical Devices Has the FDA Authorized?

As of September 2026, the FDA reported that it had authorized more than 1,600 AI-enabled medical devices for marketing in the United States. Its public list includes products across medical specialties and applications, with examples ranging from image-analysis systems to tools that support the detection or management of particular conditions.

The FDA's list is a useful indicator of the expanding regulated medical-device landscape, but the count requires three qualifications.

First, authorization is not the same as clinical adoption. A device may be authorized without being used by every hospital or clinician for whom it is relevant.

Second, the count refers to devices, not distinct AI companies, AI models or patients treated.

Third, an FDA authorization relates to a product's specified intended use and applicable regulatory requirements. It should not be interpreted as a blanket endorsement of every possible use of the underlying AI technology. The FDA says listed devices have met the applicable premarket requirements, including review relevant to their intended use and technological characteristics.

This is particularly important when distinguishing regulated medical devices from general-purpose AI chatbots. A consumer chatbot offering health information should not be assumed to have undergone the same evaluation as an authorized medical device.

Where AI Is Being Used in Healthcare

Healthcare AI is not one technology or one clinical application. Predictive models, computer vision, natural language processing and generative AI can serve very different purposesand face different standards of evidence.

Clinical documentation and ambient AI scribes

Ambient AI scribes capture a clinical conversation and produce a draft note for the clinician to review. They address a familiar problem: documentation can consume time that clinicians would otherwise spend on patient care or other work.

In the 43-health-system study, ambient notes were the only one of 37 assessed use cases for which every respondent reported at least some adoption activity. Clinical documentation was also the category with the highest share of respondents reporting a high degree of success.

There is emerging evidence of benefit, although study design matters. A multicenter U.S. quality-improvement study published in JAMA Network Open evaluated clinicians before and after 30 days of ambient AI scribe use. Among the participants included in its burnout analysis, the proportion meeting the study's burnout threshold fell from 51.9% to 38.8%. The study also reported improvements in documentation-related workload and time spent documenting after hours. Because it was a pre–post study without a randomized control group, the change cannot be attributed to the AI scribe with the same confidence as a randomized comparison.

A separate randomized trial involving 238 outpatient physicians found that results differed between the two scribes studied. One product reduced time spent writing notes by 9.5% relative to usual care, while the other did not show a statistically significant reduction on that primary measure. This is a useful reminder that outcomes from one AI product should not automatically be generalized to an entire category.

Medical imaging and radiology

AI can help analyze medical images, flag findings, support image acquisition or reconstruction and prioritize cases for review. Imaging and radiology were the most widely deployed clinical AI category in the surveyed health systems, with 90% reporting at least limited deployment.

However, deployment statistics cannot tell us whether a particular tool improves diagnostic accuracy, reduces reporting time or benefits patients. Those outcomes must be evaluated for the specific device, intended use, clinical setting and patient population.

Clinical risk prediction and decision support

Predictive AI can estimate risks such as clinical deterioration, sepsis, falls or unplanned admission. Its purpose is generally to help care teams identify patients who may need closer attention.

In the health-system survey, 67% had deployed AI for early sepsis detection in at least limited areas, while 56% had deployed tools for predicting clinical deterioration. Yet only 38% of organizations pursuing clinical risk-stratification AI reported a high degree of success.

A prediction is useful only if it is sufficiently reliable and leads to an appropriate action. False alerts can increase workload; missed cases can create safety risks. Performance may also change when a model is used with patients or clinical workflows that differ from those in which it was developed.

Patient communication and administrative work

Healthcare organizations are exploring AI to draft patient-portal responses, summarize charts, prepare instructions, support scheduling and assist with coding and revenue-cycle tasks.

The AMA survey found that 19% of responding physicians used AI to generate draft patient-portal replies and 28% used it for billing-code, chart or visit-note documentation. These are examples of AI assisting a professional workflow; they do not imply that messages or records are necessarily sent or finalized without human review.

Administrative applications can offer a more straightforward starting point than autonomous clinical decisions, but they still require controls. An inaccurate discharge instruction, coding suggestion or patient message can affect care, payment or trust.

Drug discovery and clinical research

AI can help researchers analyze biological data, explore candidate molecules, identify patterns and support parts of the research process. These applications have different timelines and success measures from AI used in hospitals.

For example, finding a promising candidate in a computational model is not equivalent to demonstrating that a medicine is safe and effective in humans. Clinical trials and the relevant regulatory requirements remain essential.

The 43-health-system survey found that AI activities for drug discovery and clinical-trial automation were still largely in development or piloting within its respondent group, rather than fully deployed hospital use cases. That finding describes the surveyed healthcare systems; it does not measure AI adoption across pharmaceutical companies or research laboratories.

Is AI Improving Healthcare Outcomes?

The answer depends on which AI system, for which patients, performing which task, compared with what alternative.

Evidence of faster documentation is not evidence of more accurate diagnosis. A model's performance on a retrospective dataset is not proof that deploying it will reduce complications or mortality. And clinicians reporting that a tool is useful is not the same as a controlled measurement of patient benefit.

The ambient-scribe studies illustrate the difference. A multicenter pre–post study found improvements in reported clinician burnout after implementation, while a randomized study found a documentation-time benefit for one scribe but not a statistically significant benefit for another on its primary measure. Both contribute useful evidence, but they answer narrower questions than whether “AI improves healthcare” overall.

A meaningful evaluation should examine the outcome relevant to the application: diagnostic accuracy and downstream care for an imaging tool; missed cases and alert burden for a risk model; note accuracy and clinician workload for a scribe; or patient understanding and safety for a communication tool.

It should also consider whether benefits persist over time and across patient groups.

What Are the Biggest Barriers to AI Adoption in Healthcare?

In the peer-reviewed survey of 43 large U.S. health systems, 77% identified immature AI tools as their largest or second-largest barrier to development or deployment. Financial concerns were cited by 47%, followed by regulatory or compliance uncertainty at 40%.

Those results help explain why a hospital can be enthusiastic about AI while remaining cautious about broad implementation.

Clinical reliability is fundamental. Healthcare systems must assess whether a tool performs adequately for its intended purpose, including when information is incomplete or circumstances change.

Workflow fit matters as well. A technically capable model may provide little benefit if it generates excessive alerts, requires clinicians to switch between systems or adds more review work than it saves.

Privacy and security are particularly consequential when AI processes sensitive health information. Organizations need to understand what data a system receives, where that data goes, who can access it and how it is retained.

Bias and equity require direct measurement. In the health-system study, only 17% of respondents said they always measured health equity or disparities when assessing AI tools. That finding points to a gap between recognizing fairness as an important goal and consistently evaluating it during implementation.

Finally, cost and evidence must be considered together. Subscription fees are only one part of implementation. Integration, training, monitoring, clinician review and governance all require resources. A product that saves time in a demonstration may not deliver the same net benefit after those costs are included.

How Do Patients Feel About AI in Healthcare?

Patient attitudes are not captured by a single global trust percentage. People may be comfortable with AI helping a radiologist analyze an image but less comfortable with an AI system making a diagnosis independently.

The supplied Statista healthcare AI overview, published in May 2026, illustrates that distinction using U.S. survey figures from 2024: it reports 60% comfort with AI in medical imaging analysis, compared with 15% comfort with AI diagnosing the respondent. Because these are summarized figures from different survey questions, they should be treated as indicators of attitudes toward particular uses not a current, universal measure of patient trust.

The practical implication is that healthcare organizations should explain AI's role clearly. Patients need to know whether a system is helping a clinician, generating a draft, analyzing information or making a recommendation and who is responsible for reviewing and acting on its output.

What Will AI in Healthcare Look Like Through 2030?

The available evidence supports continued development across documentation, imaging, decision support, administration and research. It does not support a precise prediction that AI will replace a particular share of doctors or independently manage a particular share of patient care by 2030.

The more consequential change may be integration. AI capabilities that currently operate as separate applications could become part of electronic health records, imaging systems, patient communication platforms and clinical workflows. That could reduce repetitive work, but it would also make monitoring and accountability more important.

The industry's progress should be judged against three different questions: Is the technology being adopted? Does it work reliably in its intended setting? Does its use improve outcomes that matter to clinicians and patients?

In 2026, the evidence is strongest that adoption and investment are growing. The evidence for clinical and operational benefit is more application-specific. That is not a contradiction; it is the difference between an expanding technology market and the slower work of establishing safe, effective healthcare practice.

Check also:

• AI in Real Estate Statistics

Source:

Physician adoption and AI use cases

1. AMA physician AI survey
2. AMA: Augmented intelligence in medicine

Hospital adoption, deployment and barriers

3. Peer-reviewed health-system adoption study

Market forecasts and investment

4. Grand View Research: 2030 forecast
5. Rock Health: 2025 funding report

AI-enabled medical devices

6. FDA: AI-enabled medical devices
7. FDA: List of AI-enabled medical devices

Clinical impact and ambient AI scribes

8. JAMA Network Open: Ambient AI scribe study
9. Randomized ambient AI scribe trial

Additional reference supplied for the article

1. Statista: AI in Healthcare — Statistics & Facts